Tasigna News and Research

RSS
Study provides a new target for therapeutic intervention in Parkinson's disease

Study provides a new target for therapeutic intervention in Parkinson's disease

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Cancer drug nilotinib found to be safe and well-tolerated in Alzheimer's disease clinical trial

Cancer drug shows promise in battling Parkinson’s disease

Cancer drug shows promise in battling Parkinson’s disease

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

Study shows nilotinib drug is safe and well tolerated in patients with Parkinson's disease

Study unravels how cancer medication works in brains of Parkinson's patients

Study unravels how cancer medication works in brains of Parkinson's patients

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Novartis announces FDA approval of its first and only CML therapy with TFR data in product label

Inhibition of cell receptors clears toxic proteins, cuts inflammation and improves cognition in animal models

Inhibition of cell receptors clears toxic proteins, cuts inflammation and improves cognition in animal models

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

GUMC receives FDA clearance to begin clinical study of cancer drug in patients with Alzheimer's disease

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

ADDF awards $2.1 million grant for clinical study of cancer drug in Alzheimer's patients

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novel targeted therapies and treatment combinations for leukemia

Novel targeted therapies and treatment combinations for leukemia

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Preclinical data shows BGB324 as potential treatment option for Chronic Myeloid Leukemia

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Studies confirm superiority of Tasigna to Glivec at achieving molecular response in Ph+ CML patients

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Novartis to present updates on broad cancer portfolio at ASH and SABCS symposiums

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Experimental Therapeutics, Debiopharm join to develop oral small molecules targeting new class of epigenetic modulators

Finding solutions to protect U.S. troops against invisible killers

Finding solutions to protect U.S. troops against invisible killers

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

Ponatinib to earn gold-standard status for refractory chronic myeloid leukemia in 2015

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.